# Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males

> **NCT00480467** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 32 (—)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** SAM-315

## Key facts

- **NCT ID:** NCT00480467
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 32 (—)
- **Last updated:** 2007-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00480467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00480467, "Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00480467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*